CA1338083C - Ozonides de terpenes et leur utilisation medicale - Google Patents

Ozonides de terpenes et leur utilisation medicale

Info

Publication number: CA1338083C
Authority: CA; Canada
Prior art keywords: terpene; composition; ozonide; ozonides; pharmaceutical composition
Prior art date: 1988-06-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000603585A

Other languages

English (en)

Inventor

Stephen Herman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-24

Filing date

1989-06-22

Publication date

1996-02-27

1989-06-22 Application filed by Individual filed Critical Individual

1996-02-27 Application granted granted Critical

1996-02-27 Publication of CA1338083C publication Critical patent/CA1338083C/fr

2013-02-27 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

235000007586 terpenes Nutrition 0.000 title claims abstract description 72
150000003505 terpenes Chemical class 0.000 title claims abstract description 70
239000000203 mixture Substances 0.000 claims abstract description 46
CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 36
150000001875 compounds Chemical class 0.000 claims abstract description 32
238000011282 treatment Methods 0.000 claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 24
239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 18
CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 18
229930007744 linalool Natural products 0.000 claims abstract description 18
GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims abstract description 14
-1 giberellins Chemical compound 0.000 claims abstract description 14
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 14
UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 claims abstract description 14
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 9
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 9
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 9
229940031439 squalene Drugs 0.000 claims abstract description 9
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 9
CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims abstract description 8
ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims abstract description 8
UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims abstract description 8
CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims abstract description 8
WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims abstract description 8
WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 claims abstract description 8
NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 claims abstract description 8
GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims abstract description 8
235000001510 limonene Nutrition 0.000 claims abstract description 7
229940087305 limonene Drugs 0.000 claims abstract description 7
UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 claims abstract description 7
NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 claims abstract description 4
BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims abstract description 4
CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims abstract description 4
239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims abstract description 4
CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims abstract description 4
GTPDAZPJWLNUDK-UZQQHGMGSA-N (3r,3as,5as,5bs,6ar,9s,9as)-3,5a,6a-trimethyl-9-(propan-2-yl)-2,3,3a,4,5,5a,5b,6,6a,7,8,9,9a,10-tetradecahydro-1h-pentaleno[1,6a-a]-s-indacene-11-carboxylic acid Chemical compound C1[C@@H]2[C@]3(C)CC[C@H]4[C@H](C)CCC43C(C(O)=O)=C2C[C@H]2[C@H](C(C)C)CC[C@@]21C GTPDAZPJWLNUDK-UZQQHGMGSA-N 0.000 claims abstract description 4
NVNUNRUPWXZKAL-RVUONTCYSA-N (3s,5ar,5br,7ar,11ar,11br,13ar,13bs)-3-(2-hydroxypropan-2-yl)-5a,5b,8,8,11a,13b-hexamethyl-2,3,3a,4,5,6,7,7a,10,11,11b,12,13,13a-tetradecahydro-1h-cyclopenta[a]chrysen-9-one Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CC(=O)C(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CCC1[C@]3(C)CC[C@@H]1C(C)(O)C NVNUNRUPWXZKAL-RVUONTCYSA-N 0.000 claims abstract description 4
239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 claims abstract description 4
ODJQFZXHKPCJMD-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydroazulene Chemical class C1CCCCC2CCCC21 ODJQFZXHKPCJMD-UHFFFAOYSA-N 0.000 claims abstract description 4
XBGUIVFBMBVUEG-UHFFFAOYSA-N 1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene Chemical compound CC(C)=CCCC(C)=C1CCC(C)=CC1 XBGUIVFBMBVUEG-UHFFFAOYSA-N 0.000 claims abstract description 4
XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims abstract description 4
ONVABDHFQKWOSV-UHFFFAOYSA-N 16-Phyllocladene Natural products C1CC(C2)C(=C)CC32CCC2C(C)(C)CCCC2(C)C31 ONVABDHFQKWOSV-UHFFFAOYSA-N 0.000 claims abstract description 4
VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 claims abstract description 4
GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims abstract description 4
FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims abstract description 4
MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 4
BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 claims abstract description 4
MWYYLZRWWNBROW-UHFFFAOYSA-N 6-epiophiobolin A Natural products CC1CC(C=C(C)C)OC11C2CC=C(C=O)C(C(=O)CC3(C)O)C3CC2(C)CC1 MWYYLZRWWNBROW-UHFFFAOYSA-N 0.000 claims abstract description 4
BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 claims abstract description 4
RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims abstract description 4
244000166675 Cymbopogon nardus Species 0.000 claims abstract description 4
235000018791 Cymbopogon nardus Nutrition 0.000 claims abstract description 4
CAHGCLMLTWQZNJ-WZLOIPHISA-N Euphol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@@]2(C)[C@H]([C@@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-WZLOIPHISA-N 0.000 claims abstract description 4
QFPQAPVPUNXXDR-UHFFFAOYSA-N Euphol Natural products CC(=CCCCC1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3)C QFPQAPVPUNXXDR-UHFFFAOYSA-N 0.000 claims abstract description 4
BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims abstract description 4
PATSIXWJUIPLFN-UHFFFAOYSA-N Hydroxy-hopanon Natural products CC(C)(O)C1CCC2C1(C)CCC3(C)C4CCC5C(C)(C)C(=O)CCC5(C)C4CCC23C PATSIXWJUIPLFN-UHFFFAOYSA-N 0.000 claims abstract description 4
DQUHDYWUEKWRLN-UHFFFAOYSA-N Isophyllocladen Natural products C1CC2C3(C)CCCC(C)(C)C3CCC22C=C(C)C1C2 DQUHDYWUEKWRLN-UHFFFAOYSA-N 0.000 claims abstract description 4
LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims abstract description 4
AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 claims abstract description 4
GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 claims abstract description 4
HPVHSSYMRJUBHG-UHFFFAOYSA-N Ophiobolin A Natural products CC1CC(OC12CCC3(C)CC4C(C=C(CC23)C=O)C(=O)CC4(C)O)C=C(C)C HPVHSSYMRJUBHG-UHFFFAOYSA-N 0.000 claims abstract description 4
BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 claims abstract description 4
PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims abstract description 4
GTPDAZPJWLNUDK-UHFFFAOYSA-N Retizeranic acid Natural products C1C2C3(C)CCC4C(C)CCC43C(C(O)=O)=C2CC2C(C(C)C)CCC21C GTPDAZPJWLNUDK-UHFFFAOYSA-N 0.000 claims abstract description 4
HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims abstract description 4
UXUIXVKLBWVGHM-UHFFFAOYSA-N acorane group Chemical class CC(C)C1CCC(C)C12CCC(C)CC2 UXUIXVKLBWVGHM-UHFFFAOYSA-N 0.000 claims abstract description 4
BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 claims abstract description 4
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 4
XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims abstract description 4
YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 claims abstract description 4
235000003903 alpha-carotene Nutrition 0.000 claims abstract description 4
239000011795 alpha-carotene Substances 0.000 claims abstract description 4
ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims abstract description 4
VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims abstract description 4
MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims abstract description 4
KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 claims abstract description 4
235000013734 beta-carotene Nutrition 0.000 claims abstract description 4
239000011648 beta-carotene Substances 0.000 claims abstract description 4
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 4
229960002747 betacarotene Drugs 0.000 claims abstract description 4
229930003493 bisabolene Natural products 0.000 claims abstract description 4
229930006739 camphene Natural products 0.000 claims abstract description 4
ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims abstract description 4
150000002426 caryophyllane derivatives Chemical class 0.000 claims abstract description 4
229930002312 cedrane Natural products 0.000 claims abstract description 4
125000000591 cedrane group Chemical group 0.000 claims abstract description 4
150000000121 chamigrane derivatives Chemical class 0.000 claims abstract description 4
QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims abstract description 4
150000004563 farnesanes Chemical class 0.000 claims abstract description 4
229930002886 farnesol Natural products 0.000 claims abstract description 4
229940043259 farnesol Drugs 0.000 claims abstract description 4
229930001431 germacrane Natural products 0.000 claims abstract description 4
IBMAYSYTZAVZPY-QDMKHBRRSA-N germacrane group Chemical group CC(C)[C@H]1CC[C@@H](C)CCC[C@@H](C)CC1 IBMAYSYTZAVZPY-QDMKHBRRSA-N 0.000 claims abstract description 4
229930009515 himachalene Natural products 0.000 claims abstract description 4
150000004583 himachalene derivatives Chemical class 0.000 claims abstract description 4
150000002422 hopanes Chemical class 0.000 claims abstract description 4
QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 claims abstract description 4
150000004251 humulene derivatives Chemical class 0.000 claims abstract description 4
SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 claims abstract description 4
125000001229 illudane group Chemical group 0.000 claims abstract description 4
CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims abstract description 4
229940058690 lanosterol Drugs 0.000 claims abstract description 4
AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 claims abstract description 4
150000002654 lupanes Chemical class 0.000 claims abstract description 4
MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 claims abstract description 4
PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 claims abstract description 4
150000007823 ocimene derivatives Chemical class 0.000 claims abstract description 4
BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 claims abstract description 4
MWYYLZRWWNBROW-BDZRSQQBSA-N ophiobolin A Chemical compound C[C@H]1C[C@H](C=C(C)C)O[C@]11[C@@H]2C\C=C(C=O)/[C@@H](C(=O)C[C@@]3(C)O)[C@@H]3C[C@@]2(C)CC1 MWYYLZRWWNBROW-BDZRSQQBSA-N 0.000 claims abstract description 4
ONVABDHFQKWOSV-NDLGOLERSA-N phyllocladene Chemical compound C1C[C@@H](C2)C(=C)C[C@]32CC[C@@H]2C(C)(C)CCC[C@@]2(C)[C@@H]31 ONVABDHFQKWOSV-NDLGOLERSA-N 0.000 claims abstract description 4
BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 claims abstract description 4
229930006696 sabinene Natural products 0.000 claims abstract description 4
CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims abstract description 4
XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 claims abstract description 4
OOTXFYSZXCPMPG-BMYLZFHVSA-N ursane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5[C@H]4CC[C@@H]3[C@]21C OOTXFYSZXCPMPG-BMYLZFHVSA-N 0.000 claims abstract description 4
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 3
244000097582 Cecropia peltata Species 0.000 claims abstract description 3
GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims abstract description 3
239000005792 Geraniol Substances 0.000 claims abstract description 3
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 3
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 3
229930007927 cymene Natural products 0.000 claims abstract description 3
150000000174 eudesmanes Chemical class 0.000 claims abstract description 3
229940113087 geraniol Drugs 0.000 claims abstract description 3
239000005556 hormone Substances 0.000 claims abstract description 3
229940088597 hormone Drugs 0.000 claims abstract description 3
229930002697 labdane diterpene Natural products 0.000 claims abstract description 3
150000001761 labdane diterpenoid derivatives Chemical class 0.000 claims abstract description 3
HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims abstract description 3
235000019155 vitamin A Nutrition 0.000 claims abstract description 3
239000011719 vitamin A Substances 0.000 claims abstract description 3
229940045997 vitamin a Drugs 0.000 claims abstract description 3
WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 claims description 34
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 16
241000124008 Mammalia Species 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
229940120293 vaginal suppository Drugs 0.000 claims description 3
239000006216 vaginal suppository Substances 0.000 claims description 3
239000003221 ear drop Substances 0.000 claims description 2
229940047652 ear drops Drugs 0.000 claims description 2
229940012356 eye drops Drugs 0.000 claims description 2
239000007972 injectable composition Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
238000007910 systemic administration Methods 0.000 claims 3
239000006196 drop Substances 0.000 claims 1
239000003885 eye ointment Substances 0.000 claims 1
RQIDGZHMTWSMMC-TZNPKLQUSA-N juvenile hormone I Chemical compound COC(=O)/C=C(C)/CC\C=C(/CC)CC[C@H]1O[C@@]1(C)CC RQIDGZHMTWSMMC-TZNPKLQUSA-N 0.000 claims 1
LEWJAHURGICVRE-AISVETHESA-N labdane Chemical compound CC1(C)CCC[C@]2(C)[C@@H](CC[C@H](C)CC)[C@@H](C)CC[C@H]21 LEWJAHURGICVRE-AISVETHESA-N 0.000 claims 1
229940069265 ophthalmic ointment Drugs 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
238000006243 chemical reaction Methods 0.000 description 15
206010017533 Fungal infection Diseases 0.000 description 13
238000012360 testing method Methods 0.000 description 13
208000031888 Mycoses Diseases 0.000 description 12
239000004480 active ingredient Substances 0.000 description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
239000001301 oxygen Substances 0.000 description 12
229910052760 oxygen Inorganic materials 0.000 description 12
239000003814 drug Substances 0.000 description 11
230000003902 lesion Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 10
230000000699 topical effect Effects 0.000 description 10
208000002874 Acne Vulgaris Diseases 0.000 description 9
206010000496 acne Diseases 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
238000002360 preparation method Methods 0.000 description 8
201000006082 Chickenpox Diseases 0.000 description 7
206010042496 Sunburn Diseases 0.000 description 7
206010046980 Varicella Diseases 0.000 description 7
239000000463 material Substances 0.000 description 7
231100000344 non-irritating Toxicity 0.000 description 7
238000006385 ozonation reaction Methods 0.000 description 7
RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
208000019802 Sexually transmitted disease Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000002483 medication Methods 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
208000036142 Viral infection Diseases 0.000 description 5
230000005540 biological transmission Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000007789 gas Substances 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000000622 irritating effect Effects 0.000 description 5
210000003127 knee Anatomy 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000243 solution Substances 0.000 description 5
210000001215 vagina Anatomy 0.000 description 5
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
230000007794 irritation Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000012085 test solution Substances 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
208000001688 Herpes Genitalis Diseases 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
208000010195 Onychomycosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
206010040880 Skin irritation Diseases 0.000 description 3
206010046914 Vaginal infection Diseases 0.000 description 3
239000000739 antihistaminic agent Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
201000004946 genital herpes Diseases 0.000 description 3
230000002070 germicidal effect Effects 0.000 description 3
239000002085 irritant Substances 0.000 description 3
231100000021 irritant Toxicity 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000006748 scratching Methods 0.000 description 3
230000002393 scratching effect Effects 0.000 description 3
208000017520 skin disease Diseases 0.000 description 3
230000036556 skin irritation Effects 0.000 description 3
231100000475 skin irritation Toxicity 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
201000005882 tinea unguium Diseases 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
208000003014 Bites and Stings Diseases 0.000 description 2
206010061619 Deformity Diseases 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000006877 Insect Bites and Stings Diseases 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
241000159241 Toxicodendron Species 0.000 description 2
241000159243 Toxicodendron radicans Species 0.000 description 2
230000001387 anti-histamine Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
229910001882 dioxygen Inorganic materials 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000000383 hazardous chemical Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000007803 itching Effects 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
238000011587 new zealand white rabbit Methods 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
238000005949 ozonolysis reaction Methods 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
201000004647 tinea pedis Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010003402 Arthropod sting Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012444 Dermatitis diaper Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
208000003105 Diaper Rash Diseases 0.000 description 1
206010013082 Discomfort Diseases 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
206010015946 Eye irritation Diseases 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
241001456088 Hesperocnide Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
235000009108 Urtica dioica Nutrition 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000002802 antimicrobial activity assay Methods 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000002352 blister Diseases 0.000 description 1
229940082484 carbomer-934 Drugs 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
230000001877 deodorizing effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
231100000013 eye irritation Toxicity 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000009434 installation Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940119170 jojoba wax Drugs 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
238000001256 steam distillation Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000036575 thermal burns Effects 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical class CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
MAAKQSASDHJHIR-UHFFFAOYSA-N trioxolane Chemical group C1COOO1 MAAKQSASDHJHIR-UHFFFAOYSA-N 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
229940044959 vaginal cream Drugs 0.000 description 1
239000000522 vaginal cream Substances 0.000 description 1
229940044952 vaginal foam Drugs 0.000 description 1
239000000259 vaginal foam Substances 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
- C07D323/02—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compounds Of Unknown Constitution (AREA)
Medicinal Preparation (AREA)

CA000603585A 1988-06-24 1989-06-22 Ozonides de terpenes et leur utilisation medicale Expired - Fee Related CA1338083C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21137888A	1988-06-24	1988-06-24
US211,378		1988-06-24

Publications (1)

Publication Number	Publication Date
CA1338083C true CA1338083C (fr)	1996-02-27

Family

ID=22786691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000603585A Expired - Fee Related CA1338083C (fr)	1988-06-24	1989-06-22	Ozonides de terpenes et leur utilisation medicale

Country Status (5)

Country	Link
EP (1)	EP0427781A4 (fr)
JP (1)	JPH04502145A (fr)
AU (1)	AU4058689A (fr)
CA (1)	CA1338083C (fr)
WO (1)	WO1989012626A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5364879A (en) *	1988-06-24	1994-11-15	Cliveden Ltd.	Medical uses of trioxolane and diperoxide compounds
US4983637A (en) *	1988-06-24	1991-01-08	Stephen Herman	Method for treating viral infection of HIV
US5270344A (en) *	1988-06-24	1993-12-14	Stephen Herman	Method of treating a systemic disorder using trioxolane and diperoxide compounds
JPH03170422A (ja) *	1989-11-22	1991-07-24	Dermatologic Res Corp	皮膚疾患の治療法
US5153229A (en) *	1990-06-01	1992-10-06	Doyle E. Chastain	Process for producing reference bactericidal endpoint (RBE) limonene
AUPM493194A0 (en) *	1994-04-08	1994-05-05	Buckmeier, Julie A.	Therapeutic agent for inhibiting the conversion of epithelial cells to tumours
TR199802769T2 (xx) *	1996-07-02	1999-04-21	Novartis Consumer Health S.A.	Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
US20050250757A1 (en) *	2004-05-10	2005-11-10	Hofmann Robert F	Use of targeted oxidative therapeutic formulation in treatment of cancer
WO2008001553A1 (fr) *	2006-06-28	2008-01-03	Erc Technology Inc.	Tensioactif ozonisé
WO2009086471A2 (fr) *	2007-12-27	2009-07-09	Tyratech, Inc.	Compositions antiparasites synergiques et méthodes de criblage
KR101698051B1 (ko) *	2016-01-13	2017-01-20	아주대학교산학협력단	로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물
CN108210490A (zh) *	2018-04-10	2018-06-29	武汉大学	一种雌激素受体下调剂的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US925590A (en) *	1902-07-05	1909-06-22	Oxoline Company	Process of producing a medicament.
US1210949A (en) *	1914-07-30	1917-01-02	Gen Res Lab	Medicinal compound.
US2083572A (en) *	1928-04-25	1937-06-15	Susan M Mckee	Process of treating oil
US2243053A (en) *	1931-08-30	1941-05-20	Alexander S Ramage	Process for manufacturing oxygen compounds of terpene hydrocarbons
US2356062A (en) *	1942-02-03	1944-08-15	Latimer Lab Inc	Therapeutic composition
US3504038A (en) *	1966-06-24	1970-03-31	Us Agriculture	Ozonization of vegetable oils in an improved aqueous medium
US4163800A (en) *	1977-08-17	1979-08-07	The Procter & Gamble Company	Topical composition and treatment of skin lesions therewith
US4591602A (en) *	1982-04-16	1986-05-27	James H. Brown	Ozonide esters and topical compositions containing same
US4451480A (en) *	1982-04-16	1984-05-29	James Howard Brown	Method of treating acne using ozonized materials

1989
- 1989-06-16 JP JP1508769A patent/JPH04502145A/ja active Pending
- 1989-06-16 WO PCT/US1989/002640 patent/WO1989012626A1/fr not_active Ceased
- 1989-06-16 AU AU40586/89A patent/AU4058689A/en not_active Abandoned
- 1989-06-16 EP EP19890909317 patent/EP0427781A4/en active Pending
- 1989-06-22 CA CA000603585A patent/CA1338083C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0427781A1 (fr)	1991-05-22
JPH04502145A (ja)	1992-04-16
AU4058689A (en)	1990-01-12
EP0427781A4 (en)	1991-08-21
WO1989012626A1 (fr)	1989-12-28

Legal Events

Date	Code	Title	Description
2000-02-28	MKLA	Lapsed

Publication	Publication Date	Title
US5190979A (en)	1993-03-02	Ozonides of terpenes and their medical uses
US5270344A (en)	1993-12-14	Method of treating a systemic disorder using trioxolane and diperoxide compounds
US5364879A (en)	1994-11-15	Medical uses of trioxolane and diperoxide compounds
US4983637A (en)	1991-01-08	Method for treating viral infection of HIV
US5126376A (en)	1992-06-30	Method for treating viral infection using topical administration
US5260342A (en)	1993-11-09	Method for treating viral infection parenterally
CA1338083C (fr)	1996-02-27	Ozonides de terpenes et leur utilisation medicale
MXPA04009712A (es)	2005-07-14	Procedimiento para la obtencion de aceites y grasas vegetales ozonizados y aplicacion de estos productos con fines farmaceuticos y cosmetologicos.
US5190977A (en)	1993-03-02	Antiviral compositions
DE3310079A1 (de)	1983-09-22	Topische ophthalmische arzneimittel
JPH0216728B2 (fr)	1990-04-18
DE69907193T2 (de)	2004-04-08	Vitamin e und seine ester zur verwendung in der lokale behandlung von schleimhauterkrankungen
US5086076A (en)	1992-02-04	Antiviral pharmaceutical compositions comprising a terpene ozonide
EP0191357A2 (fr)	1986-08-20	Traitement de l'ophtalmie avec du biphénamine
US5071879A (en)	1991-12-10	Systemic antiviral treatment
DK2343038T3 (en)	2015-01-26	Dermatological compositions containing a combination of peroxidized lipids and zinc and their use, especially for the treatment of herpes
US6406706B1 (en)	2002-06-18	Use of α- and β-santalols major constituents of sandal wood oil, in the treatment of warts, skin blemishes and other viral-induced tumors
DE69002946T2 (de)	1994-03-24	Paracetamol enthaltende arzneizubereitung.
CA2126757A1 (fr)	1993-07-08	Utilisation de composes trioxolane et diperoxyde en medecine
US5070107A (en)	1991-12-03	Systemic antiviral treatment
US3812250A (en)	1974-05-21	Antifungal suppository and method of treating fungus infestations
EP1663195B1 (fr)	2008-02-13	Procede pour inhiber la croissance de bacteries et de champignons pathogenes et composition microbicide
MXPA01003507A (es)	2002-06-26	Antimicrobiano sinergico, preparaciones dermatologicas y oftalmicas que contienen clorito y peroxido de hidrogeno.
US4147785A (en)	1979-04-03	Method for the treatment of onchocerciasis
CN120899927A (zh)	2025-11-07	促进局部组织一氧化氮释放水平增加的组合物及其用途